$1.84
1.66%
Nasdaq, Sep 17, 04:00 pm EDT. Closed.
ISIN
US92023M1018
Symbol
GRI

Vallon Pharmaceuticals Inc Stock price

$1.84
+0.11 6.36% 1M
-0.74 28.68% 6M
-5.07 73.37% YTD
-51.92 96.58% 1Y
-62,589.78 100.00% 3Y
-9,070,368.56 100.00% 5Y
-9,772,087.76 100.00% 10Y
-9,772,087.76 100.00% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.03 1.66%
ISIN
US92023M1018
Symbol
GRI
Industry

Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.0m
Enterprise Value
$-6.9m
Net debt
positive
Cash
$11.0m
Shares outstanding
2.2m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.7
P/B
0.4
Financial Health
Equity Ratio
69.3%
Return on Equity
-
ROCE
-94.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-9.7m
EBIT
$-9.7m
Net Income
$-9.7m
Free Cash Flow
$-10.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
3.5%
EBIT
3.5%
Net Income
19.0%
Free Cash Flow
-13.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-5.4
FCF per Share
$-4.8
Short interest
5.4%
Employees
4
Rev per Employee
-

Vallon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Vallon Pharmaceuticals Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.51 5.51
21% 21%
-
- Research and Development Expense 4.17 4.17
24% 24%
-
-9.68 -9.68
3% 3%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.68 -9.68
4% 4%
-
Net Profit -9.66 -9.66
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vallon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
10 days ago
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
Positive
New York Post
28 days ago
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
Neutral
GlobeNewsWire
3 months ago
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
More Vallon Pharmaceuticals Inc News

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Dr. Hertz
Employees 4
Founded 2009
Website www.gribio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today